Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.

Stephen C BainBrian B HansenSamuel J P MalkinSolomon NuhohoWilliam J ValentineBarrie ChubbBarnaby HuntMatthew Capehorn

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2019)

Oral semaglutide was cost-effective versus empagliflozin and sitagliptin, and dominant versus liraglutide, for the treatment of type 2 diabetes in the UK.

Keyphrases

clinical trial
study protocol
cross sectional
randomized controlled trial
open label
combination therapy
replacement therapy